Sign up to save your podcasts
Or
Share A once-monthly treatment for opioid use disorder
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
A once-monthly treatment for opioid use disorder
Mark Greenwald discusses buprenorphine extended release—a once-monthly injected formulation for the treatment of opioid use disorder recently approved by the US FDA.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet GroupMark Greenwald discusses buprenorphine extended release—a once-monthly injected formulation for the treatment of opioid use disorder recently approved by the US FDA.
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet in conversation with
View all
The Lancet Voice
23 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners